Skip to content
Finance & Wealth

Apollo Medical Founder Warren Hosseinion Net Worth: Financial Analysis & Corporate History

In this article

Dr. Warren Hosseinion, the physician-entrepreneur who co-founded Apollo Medical Holdings, Inc. (now rebranded as Astrana Health, Inc.), has built an estimated net worth ranging between $50 million and $120 million. His wealth primarily stems from foundational equity in Apollo Medical, executive compensation, stock sales documented in regulatory disclosures, and subsequent ventures in tech-enabled healthcare delivery.

Executive Overview: Financial Standing of Dr. Warren Hosseinion

Determining the precise personal net worth of corporate leaders requires examining verifiable public filings, insider trading disclosures, equity compensation arrangements, and private enterprise holdings. Dr. Warren Hosseinion’s financial profile reflects his multi-decade career as a practicing physician, chief executive officer, board member, and healthcare venture investor.

Unlike corporate executives whose wealth resides exclusively in liquid cash or real estate, Dr. Hosseinion’s net worth fluctuates directly with public equity markets, particularly within the healthcare management and clinical service sectors. As the co-founder and former Chief Executive Officer of Apollo Medical Holdings, Inc. (NASDAQ: ASTH, formerly NASDAQ: AMEH), his equity trajectory mirrors the rapid market expansion of value-based healthcare organizations over the past two decades.

Estimated Net Worth Range: $50M - $120MPrimary Wealth Drivers: Founders' Equity (ApolloMed/Astrana Health), SEC-reported Stock Liquidations, Executive Compensation, Healthcare Real Estate & Private EquityKey Regulatory Filings: SEC Form 3, Form 4, Schedule 13D/G, Schedule 14A Proxy Statements

His net worth evaluation rests upon several distinct asset classes and historical financial events:

  • Foundational Equity Holdings: Initial founder equity and accumulated share awards in Apollo Medical Holdings, Inc., which scaled into a multi-billion-dollar enterprise.
  • Public Market Executions & Liquidations: Form 4 transaction reports submitted to the U.S. Securities and Exchange Commission (SEC) detailing open-market share sales, stock option exercises, and secondary offering distributions.
  • Executive Compensation Packages: Cumulative cash salaries, performance bonuses, and share-based incentives earned during his tenure as CEO, Co-CEO, and Director of public healthcare entities.
  • Post-ApolloMed Ventures: Subsequent executive roles, equity grants, and direct investments in clinical ventures, including micro-hospital networks such as Nutex Health Inc. (NASDAQ: NUTX) and specialized medical organizations.
  • Private Clinical & Real Estate Assets: Holdings in medical groups, independent physician practice networks, and ambulatory infrastructure assets accumulated throughout his medical career.

Disclaimer: Net worth figures presented in this analysis are based on public regulatory filings, historical equity transactions, market valuations, and standardized financial modeling techniques. Private assets, personal debt obligations, and non-public financial agreements are not fully accessible to the public and may influence total individual net worth.

The Founding and Growth of Apollo Medical Holdings

To understand how Dr. Warren Hosseinion accumulated substantial capital, one must examine the corporate origin story and structural evolution of Apollo Medical Holdings.

Dr. Hosseinion earned his Medical Doctorate (M.D.) from the Georgetown University School of Medicine and completed his internal medicine residency at the Los Angeles County + USC Medical Center. Recognizing systemic inefficiencies in fee-for-service inpatient care, he co-founded Apollo Medical Holdings in 2001 alongside clinical partners. The organization initially functioned as a regional hospitalist group in Southern California, managing inpatient care and optimizing bed utilization for acute facilities.

  1. 2001: ApolloMed Founded
  2. 2008: Inpatient & Hospitalist Expansion
  3. 2014: Nasdaq / OTC Market Escalation
  4. 2017: Transformative Merger with NMM
  5. 2024+: Rebranding to Astrana Health (NASDAQ: ASTH)

Transition to Management Services Organization (MSO) Model

ApolloMed expanded beyond direct patient care into a sophisticated Management Services Organization (MSO). In healthcare finance, an MSO provides administrative, operational, IT, billing, and clinical management infrastructure to Independent Physician Associations (IPAs) and medical groups. This model allowed ApolloMed to capture value from two core financial streams:

  1. Administrative Management Fees: Stable fee-for-service revenue derived from managing physician networks, credentialing, claims processing, and compliance reporting.
  2. Capitated & Risk-Bearing Contracts: Shared-savings and risk-pool allocations under capitation agreements, where the company retained surplus funds generated by maintaining high-quality, cost-effective patient care under managed care arrangements.

This structural evolution positioned ApolloMed to capitalize on the federal shift toward value-based care mandated by the Patient Protection and Affordable Care Act (ACA). As the platform scaled, the enterprise value of ApolloMed surged, significantly multiplying the valuation of original founder equity held by Dr. Hosseinion.

Warren Buffett Net Worth Curve: Growth, Milestones & Strategy
Warren Buffett Net Worth Curve: Growth, Milestones & Strategy

Key Financial Pillars: Executive Compensation, Stock Holdings, and Transactions

Dr. Hosseinion’s wealth build-up comprises distinct liquidity events and equity milestones tracked through corporate financial filings.

1. Apollo Medical Equity & Merger Dynamics

The most substantial inflection point in Dr. Hosseinion’s net worth occurred during ApolloMed's strategic expansion and subsequent corporate combinations. In December 2017, Apollo Medical Holdings completed a transformative reverse merger with Network Medical Management, Inc. (NMM), a large-scale MSO operating extensive physician networks in California.

Prior to and immediately following the merger, Dr. Hosseinion held millions of common shares and stock options in ApolloMed. The transaction vastly enlarged the company's operating footprint, market capitalization, and institutional investment base. As ApolloMed transitioned to higher-tier exchanges—ultimately trading on the Nasdaq Global Market under the ticker ASTH (following its 2024 name change to Astrana Health)—the market value of founder shareholdings expanded rapidly.

2. Historical SEC Form 4 Disclosures & Stock Liquidations

Public regulatory records maintain an authoritative footprint of executive stock transactions. According to SEC EDGAR filings for Apollo Medical Holdings, Dr. Hosseinion executed multiple scheduled stock sales, option exercises, and share distributions during his executive tenure and post-executive transition.

  • Option Exercises: Conversion of long-held management options granted at lower strike prices into common equity.
  • Open Market Dispositions: Executed sales under SEC Rule 10b5-1 trading plans, providing structured liquidity while minimizing market impact.
  • Secondary Offerings: Participation in institutional public offerings that allowed major insiders to monetize portions of their equity holdings.

These transactions allowed Dr. Hosseinion to convert illiquid corporate equity into cash reserves and diversified investment assets over time.

Executive Compensation Components (ApolloMed / Nutex Health Era):

  • Base Salary: Annual fixed compensation ($400,000 - $750,000 range)
  • Annual Incentive Cash Bonuses: Tied to EBITDA and clinical growth targets
  • Long-Term Incentive Plan (LTIP): Restricted Stock Units (RSUs) & Stock Options
  • Founder Equity Realization: Capital gains from early-stage share issuance

3. Subsequent Leadership & Nutex Health Inc.

Following his leadership tenure at Apollo Medical Holdings, Dr. Hosseinion brought his managed-care expertise to other public and private healthcare platforms. Notably, he served as President and Director of Nutex Health Inc. (NASDAQ: NUTX), an integrated technology-enabled healthcare system operating micro-hospitals and specialty management networks.

In his executive roles at Nutex Health, Dr. Hosseinion received additional base salaries, performance bonuses, and share-based equity grants. These executive packages further diversified his earnings profile across multiple publicly traded medical enterprises.

Summary Breakdown of Financial and Corporate Milestones

The following table summarizes the structural events, executive roles, and corporate valuations that directly impacted Dr. Warren Hosseinion's net worth trajectory:

Era / Year Enterprise / Asset Executive / Ownership Role Primary Financial & Equity Impact
2001 – 2008 Apollo Medical Holdings Co-Founder, Chief Executive Officer Establishment of initial founder equity; rollout of inpatient hospitalist contracts.
2008 – 2014 ApolloMed Platform CEO, Director, Major Shareholder Transformation into MSO model; preliminary public listing via over-the-counter and junior markets.
2014 – 2017 Apollo Medical Holdings Co-CEO, Director Acquisition of regional IPAs; preparation for institutional capital markets expansion.
2017 – 2019 ApolloMed / NMM Merger Co-CEO, Board Member Execution of landmark merger with Network Medical Management; significant increase in market cap and equity valuation.
2019 – 2022 Board & Investment Period Board Director, Private Investor Monetization of shares via Rule 10b5-1 plans; deployment of private equity into specialized clinical groups.
2022 – Present Nutex Health / Rebranded Astrana Health President (Nutex), Strategic Investor Executive compensation and equity grants at Nutex; participation in value-based platform scaling.

Value-Based Healthcare Business Models & Founder Wealth Generation

To evaluate why founders of MSOs like Apollo Medical build high net worths relative to traditional medical practitioners, it is necessary to examine the underlying financial dynamics of modern managed care.

  • Traditional Fee-for-Service Model:

    1. Patient Visit
    2. Direct Billing
    3. Variable Revenue (Linear Scalability)
  • MSO / Value-Based Care Model:

    1. Capitated Lives
    2. Risk-Bearing Organization
    3. Shared Savings Pool + Administrative Margin
    4. Enterprise Equity Multiple

Capitation vs. Fee-for-Service Economics

In traditional clinical medicine, physician earnings scale linearly: income is tied directly to the physical volume of patient consultations, procedures, or hospital shifts performed. This creates a hard ceiling on individual earnings potential.

By contrast, physician-entrepreneurs who establish MSOs and Risk-Bearing Organizations (RBOs) tap into scaled risk-adjustment financial models:

  • Capitated Premium Management: Under capitation contracts with health plans, the MSO receives a fixed monthly dollar amount per patient (Per Member Per Month or PMPM) regardless of whether the patient seeks care.
  • Medical Loss Ratio (MLR) Optimization: If the MSO manages clinical outcomes efficiently—reducing preventable hospital readmissions and emergency department utilization—the operational margin remains with the organization as net income.
  • Valuation Multiples on EBITDA: Managed care companies and MSOs trade on public exchanges at multiples of their Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). This converts operational efficiency into high public enterprise valuations.

Dr. Hosseinion’s strategic decision to scale ApolloMed as a technology-enabled MSO positioned his equity to benefit from equity market multiples, rather than relying solely on personal clinical billing.

SEC Transparency and Regulatory Verification Mechanisms

Under United States federal securities law, public enterprise founders and executive officers are subject to stringent disclosure guidelines enforced by the SEC. These public disclosures allow financial analysts to trace executive net worth components with high precision.

Key Disclosure Documents Used in Net Worth Analysis

  1. Form 3 (Initial Statement of Beneficial Ownership of Securities): Filed when an individual becomes an insider, establishing the baseline stock holdings owned directly or indirectly.
  2. Form 4 (Statement of Changes in Beneficial Ownership): Required within two business days of any purchase, sale, option exercise, or equity grant. These documents disclose exact share quantities, transaction prices, and remaining ownership balances.
  3. Schedule 13D and 13G: Disclosures required when an individual or group acquires more than 5% of a public company's voting equity class, providing transparency into major founder stakes.
  4. Schedule 14A (Proxy Statement): Annual filings detailing executive compensation packages, including base salary, non-equity incentive compensation, option awards, stock grants, and executive perquisites.

For instance, past proxy disclosures for Apollo Medical Holdings filed on the SEC EDGAR System illustrate the multi-million-dollar annual compensation packages and equity grants provided to top executive officers, establishing a clear public record of cumulative baseline earnings.

Comparative Analysis: Physician-Founders in Managed Care

Dr. Warren Hosseinion's financial trajectory fits into a broader macroeconomic trend: the emergence of physician-led corporate platforms within the U.S. healthcare economy. Comparing his financial structure with peer founders highlights how value-based care creates substantial executive equity.

Clinical Practitioner Physician Entrepreneur / MSO Leader
• Fee-for-service compensation • Risk-pool capitation revenues
• Income capped by practice hours • Enterprise valuation multiples
• Minimal equity leverage • Public market equity & option liquidations
• Local footprint • Regional/National expansion

When physicians lead the corporate platforms that aggregate medical practices, their financial outcomes decouple from standard clinical salary bands. By operating at the intersection of clinical care, corporate governance, and capital markets, leaders like Dr. Hosseinion retain substantial equity in entity-wide revenue streams, resulting in net worth levels in the multi-million-dollar range.

Frequently Asked Questions (FAQs)

What is the estimated net worth of Apollo Medical founder Dr. Warren Hosseinion?

Dr. Warren Hosseinion's net worth is estimated between $50 million and $120 million. This estimate is derived from SEC filings reporting his equity holdings in Apollo Medical Holdings (now Astrana Health), historical stock sales, executive compensation, and investments in other healthcare enterprises like Nutex Health Inc.

How did Dr. Warren Hosseinion accumulate his wealth?

His primary wealth accumulation occurred through co-founding Apollo Medical Holdings in 2001. As the company grew into a major public Management Services Organization (MSO) and executed strategic mergers—such as its 2017 combination with Network Medical Management—his founder equity increased significantly in value. He also earned substantial executive compensation and realized capital gains through open-market stock sales.

What was Dr. Hosseinion’s role at Apollo Medical Holdings?

Dr. Hosseinion co-founded Apollo Medical Holdings, Inc. and served as its Chief Executive Officer (CEO) and Director for many years. Following the company's major corporate merger with Network Medical Management in 2017, he served as Co-CEO and continued to guide the organization's strategic expansion in value-based healthcare.

What is Apollo Medical Holdings known as today?

Apollo Medical Holdings rebranded as Astrana Health, Inc. (NASDAQ: ASTH) to reflect its expanded nationwide healthcare delivery, management, and technology capabilities.

Does Dr. Warren Hosseinion still own shares in Apollo Medical (Astrana Health)?

While Dr. Hosseinion stepped down from executive management, public filings indicate he has historically held significant share positions and options. Executives and founders routinely diversify their portfolios over time using SEC Rule 10b5-1 pre-scheduled trading plans, meaning exact equity stakes vary depending on periodic public disclosures.

Key Takeaways for Financial Analysts and Investors

Evaluating the net worth of physician-entrepreneurs like Dr. Warren Hosseinion provides valuable insights into how corporate healthcare delivery creates equity value.

  • MSO Platform Scaling: Founding and scaling an MSO offers significant financial upside compared to traditional clinical practice by capitalizing on managed care contracts and risk-bearing pools.
  • Public Market Liquidity: Public listing events (such as ApolloMed's ascent to Nasdaq) allow founders to convert enterprise equity into liquid capital through regulated Form 4 transactions.
  • Diversification into Secondary Ventures: Experienced healthcare founders frequently reinvest capital and operational expertise into adjacent public and private healthcare models (such as micro-hospitals and specialty practice groups).

Investors and analysts seeking to track Dr. Hosseinion's ongoing financial activities can monitor insider transaction reports via the SEC EDGAR Database under associated publicly traded tickers, including ASTH and NUTX.